FDA: Birth control pill ad misleading

The U.S. Food and Drug Administration recently told Berlex Laboratories, a unit of Schering AG, that a TV ad for its birth control pill, Yasmin, is misleading. The ad overstates how well the drug works and understates its health risks, the FDA said, ordering the company to stop running the ad.

Titled "Goodbye Kiss," the ad suggested Yasmin is better than other pills because it contains progestin drospirenone, a synthetic form of the hormone progesterone. Drospirenon was associated with major blood clots in one European study.

Read the FDA's letter to the drug company.